Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said
Respiration substrate ADP was added to the chamber
We dont know. Health Secretary Robert F
Tershner SA, Mitchell JM, Fields HL
Combination procedures extend recovery proportionally, often requiring 3-4 weeks before returning to normal daily activities
Larger weight loss typically becomes apparent by week 6-8 as your body fully adjusts